Potassium Phosphate Injection Shortage
Last Updated: February 5, 2025
Status: Current
Products Affected - Description
-
- Potassium Phosphate injection, CMP Pharma, 3 mmol/mL, 15 mL vial, 10 count, NDC 46287-0024-10 - discontinued
- Potassium Phosphate injection, Pfizer, 3 mmol/mL, 15 mL vial, 25 count, NDC 00409-7295-01
Reason for the Shortage
-
- American Regent has potassium phosphate injection available.
- Amneal has potassium phosphate injection available.
- CMP Pharma discontinued potassium phosphate injection in 2024.
- Fresenius Kabi did not provide a reason for the shortage.
- Pfizer has potassium phosphate injection on shortage due to manufacturing delays.
- Somerset has potassium phosphate injection available.
Available Products
-
- Potassium Phosphate injection, American Regent, 3 mmol/mL, 15 mL vial, 25 count, NDC 00517-2102-25
- Potassium Phosphate injection, American Regent, 3 mmol/mL, 5 mL vial, 25 count, NDC 00517-2051-25
- Potassium Phosphate injection, American Regent, 3 mmol/mL, 50 mL vial, 25 count, NDC 00517-2505-25
- Potassium Phosphate injection, Amneal, 3 mmol/mL, 15 mL vial, 30 count, NDC 80830-1691-02
- Potassium Phosphate injection, Amneal, 3 mmol/mL, 5 mL vial, 30 count, NDC 80830-1693-03
- Potassium Phosphate injection, Amneal, 3 mmol/mL, 50 mL vial, 15 count, NDC 80830-1692-02
- Potassium Phosphate injection, Somerset Therapeutics LLC, 3 mmol/mL, 15 mL vial, 25 count, NDC 70069-0747-25
- Potassium Phosphate injection, Somerset Therapeutics LLC, 3 mmol/mL, 5 mL vial, 25 count, NDC 70069-0746-25
- Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 15 mL vial, 25 count, NDC 65219-0054-29
- Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 5 mL vial, 25 count, NDC 65219-0052-29
- Potassium Phosphate injection, Fresenius Kabi, 3 mmol/mL, 50 mL vial, 25 count, NDC 65219-0056-29
Estimated Resupply Dates
-
- Pfizer has potassium phosphate 3 mmol/mL 15 mL vials on back order and the company estimates a release date of December 2028.
Safety
-
- FDA continues to be concerned about the risk of aluminum toxicity associated with unapproved potassium phosphate products in pediatric patients. Pfizer (Hospira) has agreed to stop distributing their unapproved product within 90 days of August 1, 2024. There are generic products that have been approved since February 2023 that have acceptable aluminum levels. More information can be found at: https://www.fda.gov/drugs/drug-safety-and-availability/infants-risk-aluminum-toxicity-unapproved-potassium-phosphates-drug-product
Updated
Updated February 5, 2025 by Michelle Wheeler, PharmD, Drug Information Specialist. Created September 1, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2025, Drug Information Service, University of Utah, Salt Lake City, UT.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.